The LENNY trial highlighted the system's efficacy and safety in children aged two to six years with type 1 diabetes.

Medtronic announced today that it received CE mark for its LigaSure vessel sealing technology for use with its Hugo system.

Medtronic said its market-leading LigaSure technology can now be used with its Hugo soft tissue robotic surgery system in ...

With EU CE mark clearance for LigaSure RAS, Medtronic expands the Hugo system’s capabilities in gynaecologic and urologic ...

The company continued to gain global market share with its LigaSure advanced energy products, achieving 11 consecutive quarters of share gains.

Medtronic has secured EU CE mark approval for LigaSure RAS, a vessel-sealing instrument for use with the company’s Hugo robotic-assisted surgery (RAS) system.